Entrada Therapeutics Inc
NASDAQ:TRDA
Entrada Therapeutics Inc
Interest Income Expense
Entrada Therapeutics Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
Interest Income Expense
$15.2m
|
CAGR 3-Years
377%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$757m
|
CAGR 3-Years
35%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$563.1m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Entrada Therapeutics Inc's Interest Income Expense?
Interest Income Expense
15.2m
USD
Based on the financial report for Dec 31, 2023, Entrada Therapeutics Inc's Interest Income Expense amounts to 15.2m USD.
What is Entrada Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
377%
Over the last year, the Interest Income Expense growth was 479%. The average annual Interest Income Expense growth rates for Entrada Therapeutics Inc have been 377% over the past three years .